Hikma Pharmaceuticals (HIK) Competitors GBX 1,836 +15.00 (+0.82%) As of 08/22/2025 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock HIK vs. HCM, INDV, AMYT, AGY, APH, ANCR, VLG, STX, EAH, and DNLShould you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), Shield Therapeutics (STX), ECO Animal Health Group (EAH), and Diurnal Group (DNL). These companies are all part of the "drug manufacturers - specialty & generic" industry. Hikma Pharmaceuticals vs. Its Competitors HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Animalcare Group Venture Life Group Shield Therapeutics ECO Animal Health Group Diurnal Group Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Which has more volatility & risk, HIK or HCM? Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Does the media refer more to HIK or HCM? In the previous week, Hikma Pharmaceuticals had 4 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 1.12 beat HUTCHMED's score of -0.78 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Do analysts prefer HIK or HCM? Hikma Pharmaceuticals presently has a consensus target price of GBX 2,627.50, suggesting a potential upside of 43.11%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is HIK or HCM more profitable? Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.Company Net Margins Return on Equity Return on Assets Hikma Pharmaceuticals9.45% 12.71% 9.40% HUTCHMED -6.87%-5.71%-5.90% Which has preferable valuation & earnings, HIK or HCM? Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHikma Pharmaceuticals£3.74B1.36£353.21M£101.9118.02HUTCHMED£771.01M3.37-£52.98M-£3.92-61.00 Do institutionals and insiders believe in HIK or HCM? 42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 39.0% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryHikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks. Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIK vs. The Competition Export to ExcelMetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£5.09B£2.27B£5.76B£3.22BDividend Yield2.65%2.92%4.40%5.04%P/E Ratio18.024.3230.19164.70Price / Sales1.36691.67474.98310,111.42Price / Cash8.3410.3725.7827.93Price / Book1.7911.949.425.91Net Income£353.21M£20.70B£3.27B£5.89B7 Day Performance1.91%1.29%2.05%49.44%1 Month Performance-8.38%4.70%3.58%58.03%1 Year Performance-8.84%5.11%30.09%141.20% Hikma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HIKHikma Pharmaceuticals4.2043 of 5 starsGBX 1,836+0.8%GBX 2,627.50+43.1%-8.8%£5.09B£3.74B18.029,100Positive NewsInsider TradeHCMHUTCHMEDN/AGBX 245.89+4.6%N/A-9.1%£2.67B£771.01M-62.761,760News CoverageHigh Trading VolumeINDVIndivior2.4447 of 5 starsGBX 1,238+1.6%GBX 1,650+33.3%+33.8%£1.93B£1.40B-1,026.481,000Gap UpHigh Trading VolumeAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 8.75+4.2%N/A+87.1%£430.07M£72.18M-8.43612Gap UpAPHAlliance Pharma1.8899 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 262-1.1%N/A-4.0%£179.63M£84.90M4.88220VLGVenture Life GroupN/AGBX 60.69+4.6%N/A+25.9%£77.33M£51.77M102.99165News CoverageSTXShield TherapeuticsN/AGBX 7+7.7%N/A+117.1%£69.08M£20.92M-1.8040,000News CoverageGap UpHigh Trading VolumeEAHECO Animal Health Group3.6829 of 5 starsGBX 73.46-0.1%GBX 150+104.2%N/A£49.78M£89.44M47.49234DNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133 Related Companies and Tools Related Companies HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Animalcare Group Alternatives Venture Life Group Alternatives Shield Therapeutics Alternatives ECO Animal Health Group Alternatives Diurnal Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:HIK) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.